Search

Your search keyword '"Dubin, Celina"' showing total 19 results
Start Over Author "Dubin, Celina"
19 results on '"Dubin, Celina"'

1. A phase 2a trial of brepocitinib for cicatricial alopecia

Author

David, Eden, Shokrian, Neda, Del Duca, Ester, Meariman, Marguerite, Dubin, Celina, Hawkins, Kelly, Andrews, Elizabeth, Sikand, Savina, Singer, Giselle, Oemar, Barry, Estrada, Yeriel, Bose, Swaroop, Pulsinelli, Juliana, Mahling, Ping, Da Rosa, Joel Correa, Ungar, Benjamin, Peeva, Elena, and Guttman-Yassky, Emma

Published
2024
Full Text
View/download PDF

2. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement

Author

Dubin, Celina, Glickman, Jacob W., Del Duca, Ester, Chennareddy, Sumanth, Han, Joseph, Dahabreh, Dante, Estrada, Yeriel D., Zhang, Ning, Kimmel, Grace W., Singer, Giselle, Chowdhury, Mashkura, Zheng, Andrew Y., Angelov, Michael, Gay-Mimbrera, Jesús, Ruano Ruiz, Juan, Krueger, James G., Pavel, Ana B., and Guttman-Yassky, Emma

Published
2022
Full Text
View/download PDF

8. COVID-19 symptoms are attenuated in atopic dermatitis patients treated with dupilumab Short running title: Reduced COVID-19 symptoms in dupilumab-treated AD

Author

Ungar, Benjamin, primary, Glickman, Jacob W., additional, Golant, Alexandra, additional, Dubin, Celina, additional, Marushchak, Olga, additional, Gontzes, Alyssa, additional, Mikhaylov, Daniela, additional, Singer, Giselle, additional, Baum, Danielle, additional, Wei, Nancy, additional, Gruenstein, Diana, additional, Lebwohl, Mark, additional, Pavel, Ana Brandusa, additional, and Guttman-Yassky, Emma, additional

Published
2024
Full Text
View/download PDF

12. An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata

Author

Glickman, Jacob W., primary, Dubin, Celina, additional, Dahabreh, Dante, additional, Han, Joseph, additional, Del Duca, Ester, additional, Estrada, Yeriel D., additional, Zhang, Ning, additional, Kimmel, Grace W., additional, Singer, Giselle, additional, Krueger, James G., additional, Pavel, Ana B., additional, and Guttman‐Yassky, Emma, additional

Published
2021
Full Text
View/download PDF

13. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges

Author

Dubin,Celina, Del Duca,Ester, and Guttman-Yassky,Emma

Subjects
integumentary system, Therapeutics and Clinical Risk Management
Abstract

Celina Dubin,1 Ester Del Duca,1,2 Emma Guttman-Yassky1,3 1Department of Dermatology, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Department of Dermatology, University of Magna Graecia, Catanzaro, Italy; 3Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USACorrespondence: Emma Guttman-YasskyDepartment of Dermatology, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 E. 98th Street, New York, NY 10029, USATel +1 212-241-9728Fax +1 212-876-8961Email Emma.Guttman@mountsinai.orgAbstract: Chronic hand eczema (CHE) is a common and burdensome inflammatory skin condition seen in up to 10% of the population, more often in high-risk occupational workers. Topical therapeutics comprise the standard of care, but up to 65% of cases do not resolve after treatment, and moderate-to-severe cases are often resistant to topical therapeutics and require systemic options instead. To date, there are no systemic therapeutics approved to treat CHE in the United States, but several drugs are under investigation as potential treatments for CHE. The primary focus of this review is on the novel therapeutics, topical and systemic, that are under investigation in recently completed or currently ongoing trials. This review also briefly outlines the existing treatments utilized for CHE, often with limited success or extensive adverse effects. CHE represents a major challenge for physicians and patients alike, and efforts to improve the minimally invasive diagnostic tools and treatment paradigms are ongoing. In the near future, CHE patients may benefit from new topical and systemic therapeutics that specifically target abnormally expressed immune markers.Keywords: AFX5931, chronic hand eczema, delgocitinib, dupilumab, gusacitinib, roflumilast

Published
2020

14. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]

Author

Dubin,Celina, Del Duca,Ester, Guttman-Yassky,Emma, Dubin,Celina, Del Duca,Ester, and Guttman-Yassky,Emma

Abstract

Dubin C, Del Duca E, Guttman-Yassky E. Ther Clin Risk Manag. 2020;16:1319– 1332. The authors have advised the drug, ARQ-252, was misnamed in the paper as roflumilast (which is called ARQ-151 and ARQ-154 by the manufacturer). The drug named ARQ-252 by the manufacturer should instead be classified as a JAK1 inhibitor in the paper. On page 1320, CHE Treatment Paradigm section, 1st paragraph, “There are also ongoing studies with phosphodiesterase type 4 inhibitors (PDE4) and inhibitors of highly inflammatory chemokines CCL2 and CCL5 for the treatment of mild to moderate CHE. 1,35– 38” should read “There are also ongoing studies with topical JAK1 inhibitors and inhibitors of highly inflammatory chemokines CCL2 and CCL5 for the treatment of mild to moderate CHE. 1,35– 38”. On page 1322, Table 1, Agent and Target/Mechanism columns, “Roflumilast (ARQ-252)” should read “ARQ-252” and “PDE4” should read “JAK1”. On page 1323, before Roflumilast section, new section added for ARQ-252:ARQ-252Another topical JAK inhibitor is currently under investigation for the treatment of CHE. ARQ-252, a topical JAK1 inhibitor, is under clinical evaluation in a phase 1/2b randomized parallel assignment trial involving 223 patients with chronic hand eczema. 37,90 On page 1323, Roflumilast section now reads “Roflumilast is a high potency selective inhibitor of the receptor for PDE4, which functions by degrading cyclic adenosine monophosphate (cAMP). 89 Blocking the PDE-4 receptor allows cAMP to signal the transcription of immune function genes such as anti-inflammatory IL-10, while simultaneously reducing the production of inflammatory&

Published
2021

19. COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab

Author

Ungar, Benjamin, Glickman, Jacob W., Golant, Alexandra K., Dubin, Celina, Marushchak, Olga, Gontzes, Alyssa, Mikhaylov, Daniela, Singer, Giselle K., Baum, Danielle, Wei, Nancy, Sanin, Antonio, Gruenstein, Diana, Lebwohl, Mark G., Pavel, Ana B., and Guttman-Yassky, Emma

Abstract

In the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the type 2/Th2 polarized skin disease, atopic dermatitis (AD).

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results